대한의생명과학회지 (Biomedical Science Letters)

  • 제24권1호
  • /
  • Pages.9-14
  • /
  • 2018
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Assessment of Ki-67 for Predicting Effective Prognosis in Breast Cancer Subtypes

  • Park, Sangjung (Department of Biomedical Laboratory Science, College of Life and Health Sciences, Hoseo University) ;
  • Park, Sunyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Kim, Jungho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Ahn, Sungwoo (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Park, Kwang Hwa (Department of Pathology, College of Medicine, Yonsei University Wonju) ;
  • Lee, Hyeyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
  • 투고 : 2017.11.29
  • 심사 : 2018.01.24
  • 발행 : 2018.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ki-67 has been widely performed and become an important biomarker in worldwide clinics, but the standard cut off value of Ki-67 index in breast cancer is still controversy. The objective study was to understand the Ki-67 in breast cancer subtypes and to investigate relative risk of breast cancer subtypes according to Ki-67 cut off value in Korean breast cancer. Immunohistochemical staining (IHC) for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 index was examined from 123 breast cancer patients. Ki-67 index was significantly overexpressed in PR, ER, and HER2 hormone negative groups. Ki-67 index in Triple negative and HER2 subtypes was shown significantly higher than that in Luminal A and Luminal B subtype. Then, we compared the relative risk of each subtype according to 14% and 20% Ki-67 cut off value, which were applied in most clinics. Especially, 20% Ki-67 cut off value in HER2 and Triple negative subtypes was shown 8.41 fold and 2.83 fold higher relative risk than this in Luminal A subtype. Moreover, Ki-67 index in HER2 2+ or 3+ status showed significantly overexpressed than this in HER2 1+ status. At the 20% Ki-67 cut off value, HER2 1+ or 2+ status and 3+ status showed significant difference. Therefore, the 20% Ki-67 cut off value will be useful as a precise prognostic management and helpful for interpreting diverse outcomes of other subtypes in breast cancer patients.

키워드

참고문헌

  1. Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, Papotti M, Sapino A, Castellano I. Optimal Ki-67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a long-term follow-up. Breast Cancer Research Treatment. 2016. 157: 363-371. https://doi.org/10.1007/s10549-016-3817-9
  2. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki-67 index, her2 status, and prognosis of patients with luminal B breast cancer. Journal of National Cancer Institute. 2009. 101: 736-750. https://doi.org/10.1093/jnci/djp082
  3. Chung YR, Jang MH, Park SY, Gong G, Jung WH, Korean Breast Pathology Ki-67 Study G. Interobserver variability of Ki-67 measurement in breast cancer. Journal of Pathology and Translational Medicine. 2016. 50: 129-137. https://doi.org/10.4132/jptm.2015.12.24
  4. Denkert C, von Minckwitz G. Reply to Ki-67 in breast cancer: A useful prognostic marker! Annals of Oncology. 2014. 25: 542-543.
  5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. Strategies for subtypes--dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology. 2011. 22: 1736-1747. https://doi.org/10.1093/annonc/mdr304
  6. Kim TJ, Kim SC. Analysis of the bcl-2, Ki-67 and p53 expression level based on the Gleason score group of prostate adenocarcinoma. Biomedical Science Letter. 2008. 14: 156-165.
  7. Kim Y, Seok JY, Hyun KY, Lee GH, Choi SC. Correlation of Glasgow pronostic score or procalcitonin to clinical variables in patients with pretreatment lung cancer. Biomedical Science Letter. 2016. 22: 9-17. https://doi.org/10.15616/BSL.2016.22.1.9
  8. Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011. 78: 99-114. https://doi.org/10.1159/000292644
  9. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, Cremoux P, Bellocq JP. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Research Treatment. 2012. 132: 895-915. https://doi.org/10.1007/s10549-011-1837-z
  10. Moerland E, Van Hezik RL, Van Der Aa TC, Van Beek MW, Van Den Brule AJ. Detection of her2 amplification in breast carcinomas: Comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) combined with automated spot counting. Cellular Oncology. 2006. 28: 151-159.
  11. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clinical Cancer Research. 2010. 16: 6100-6110. https://doi.org/10.1158/1078-0432.CCR-10-1533
  12. Shokouh TZ, Ezatollah A, Barand P. Interrelationships between Ki-67, her2/neu, p53, er, and pr status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes retrospective-observational analytical study. Medicine. 2015. 94: e1359. https://doi.org/10.1097/MD.0000000000001359
  13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016. 66: 7-30. https://doi.org/10.3322/caac.21332
  14. Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki-67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. International Journal of Clinical and Experimental Pathology. 2014. 7: 6862-6870.
  15. Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y, Arima N. Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: A retrospective study. PLOS One. 2015. 10: e0119565. https://doi.org/10.1371/journal.pone.0119565
  16. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, International Breast Cancer Study G. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer. 2003. 97: 1321-1331. https://doi.org/10.1002/cncr.11188
  17. Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX. Relation between Ki-67, ER, PR, HER2/Neu, p21, EGFR, and Top II-alpha expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pacific Journal of Cancer Prevention. 2015. 16: 823-829. https://doi.org/10.7314/APJCP.2015.16.2.823